EP Patent

EP3026122A1 — Cellular-based method for determining the potency of defibrotide

Assigned to Gentium SRL · Expires 2016-06-01 · 10y expired

What this patent protects

The present invention relates to cell-based methods for determining the biological activity of defibrotide. In particular, the invention provides a method for assessing the potency of defibrotide by assessing the viability of mammalian cells in the presence of at least one cytoto…

USPTO Abstract

The present invention relates to cell-based methods for determining the biological activity of defibrotide. In particular, the invention provides a method for assessing the potency of defibrotide by assessing the viability of mammalian cells in the presence of at least one cytotoxic agent and one or more concentrations of defibrotide. Such methods are particularly useful for standardizing pharmaceutical compositions comprising defibrotide.

Drugs covered by this patent

Patent Metadata

Patent number
EP3026122A1
Jurisdiction
EP
Classification
—
Expires
2016-06-01
Drug substance claim
No
Drug product claim
No
Assignee
Gentium SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.